Use of the dialysis products GranuFlo® and NaturaLyte® has been linked to an up to six-fold increase in the risk of cardiopulmonary arrest and sudden cardiac death. The manufacturer, Fresenius Medical Care, was aware of the injuries and dangers associated with their dialysis products but failed to warn patients and doctors until 2012. The result has placed more than half of all dialysis patients in the United States at risk, and set the stage for imminent lawsuits.
The company’s slow response placed more dialysis patients at risk, despite evidence that high pre-dialysis serum bicarbonate levels created a risk of cardiac arrest and deaths.
Despite patient safety issues and potential GranuFlo lawsuits, Fresenius Medical Care continues to aggressively market the products and routinely bundles GranuFlo and/or NaturaLyte with other FMC products for pricing discounts.
It is estimated that 3,300 dialysis clinics, servicing approximately 260,000 dialysis patients, are currently using these potentially harmful formulations.
Research Behind the GranuFlo® and NaturaLyte® Recall
Medical research links GranuFlo® and NaturaLyte® to high bicarbonate levels that can cause a variety of health problems including:
- Cardiopulmonary arrest
- Heart problems
- Metabolic alkalosis
- Low blood pressure
- Sudden MI or heart attack
The GranuFlo® and NaturaLyte® recall states that the company failed to disclose vital information to the FDA and health-care providers about the possible risk of high bicarbonate levels when administering these products.
If you suspect that you or a loved one has been injured by one of these two dialysis drugs, contact Alexander Shunnarah Personal Injury Attorneys immediately at 1-800-229-7989. Our pharmaceutical injury attorneys can keep you advised on further investigations and the action to take in a lawsuit.